FUNDAMENTALS
EdgeFII/DII
DIVISLABDivis Laboratories
₹11,180.50+0.02%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
DIVISLABNSE · EquityPharmaceuticals

Divis Laboratories

ISIN
INE361B01024
Instrument key
NSE_EQ|INE361B01024
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹11,180.50+2.50 · +0.02%
Day rangecircuit ₹10,062.50 – ₹12,298.50
11,025.00
11,198.00

as of 21/11/2026, 3:10:08 pm

Open
₹11,125.00
Day high
₹11,198.00
Day low
₹11,025.00
Prev. close
₹11,178.00
Volume
4.05 L
VWAP
₹11,113.02

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

Max · monthly candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M6M1Y5YMAX
Change · MAX
+101911.86%
10.96 → 11,180.50
Period high
₹11,824.00
1/11/2026
Period low
₹7.75
1/3/2003
From high
-5.44%
+144164.52% from low
Avg volume
1.92 Cr
546.80 Cr total
Volatility · ann.
39.7%
285 candles · 173 up / 112 down
1 Nov 2026O 9,900.00H 11,824.00L 9,863.00C 11,180.50Vol 1.30 Cr
SMA 20SMA 50Averages need 50 candles before they begin
Candle data285 rows of open, high, low, close and volumeShowHide
1 Nov 20269,900.0011,824.009,863.0011,180.50+12.93%1,961.001.30 Cr
1 Oct 20269,277.009,865.008,797.009,780.00+5.42%1,068.001.23 Cr
1 Sept 20269,251.509,740.008,923.009,291.50+0.43%817.001.05 Cr
1 Aug 20268,380.009,467.008,105.009,467.00+12.97%1,362.001.06 Cr
1 Jul 20266,599.008,090.006,530.508,056.00+22.08%1,559.501.12 Cr
1 Jun 20266,690.006,887.506,450.506,579.00-1.66%437.0073.88 L
1 May 20266,508.006,968.006,483.506,667.00+2.44%484.5070.56 L
1 Apr 20266,002.006,549.505,647.506,502.50+8.34%902.0062.76 L
1 Mar 20266,271.506,479.005,901.505,947.00-5.17%577.5051.90 L
1 Feb 20266,080.506,793.005,890.006,408.50+5.39%903.0080.38 L

Historical price and volume data · Showing 1–10 of 285

1 / 29

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

88.41
Company
88.41
Sector
-45.02

Worse than sector by 296%

P/B

Price ÷ book value per share

16.52
Company
16.52
Sector
4.21

Worse than sector by 292%

ROA

Net income ÷ total assets

15.31%
Company
15.31%
Sector
1.19%

Better than sector by 1187%

ROE

Net income ÷ shareholders' equity

18.69%
Company
18.69%
Sector
-0.4%

Better than sector by 4772%

ROCE

EBIT ÷ capital employed

23.83%
Company
23.83%
Sector
15.44%

Better than sector by 54%

Quick Ratio

Liquid assets ÷ current liabilities

3.5
Company
3.5
Sector
4.8

Worse than sector by 27%

EV/EBITDA

Enterprise value ÷ EBITDA

59.23
Company
59.23
Sector
22.86

Worse than sector by 159%

04/Business

About the company

Sector: Pharmaceuticals

Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, Vigabatrin, and others. The Company is also engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG.

Sector market cap (INR)
₹2,97,325 Cr

reported in crore

Sector market cap (USD)
$33.04B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Consolidated income statement

Annual figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Mar 2026
₹11,067 Cr
+13.95% vs Mar 2025
Net profit · Mar 2026
₹2,568 Cr
+17.21% vs Mar 2025
Operating margin
30.6%
was 30.0%
Revenue CAGR · 4p
10.9%
profit 12.1% · op 12.7%
Filed order
Revenue11,0679,7128,1848,112
Revenue growthreported13.9%18.7%0.9%—
Operating profit3,3882,9162,1632,369
Operating profit growthreported16.2%34.8%-8.7%—
Operating marginderived30.6%30.0%26.4%29.2%
Net profit2,5682,1911,6001,824
Net profit growthreported17.2%36.9%-12.3%—
Net marginderived23.2%22.6%19.6%22.5%
EPS — basic₹/share, annual96.7582.5360.2768.69

Figures in ₹ crore. Margin rows are computed from the reported values.

Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
Filed order
Revenue10,5609,3607,8457,768
Other Income507352339345
Total Revenue11,0679,7128,1848,112
Total Expenses7,6056,7966,0215,744
Profit Before Tax3,3882,9162,1632,369
Tax820725563545
Profit After Tax2,5682,1911,6001,823
EPS - Basic96.7582.5360.2768.69
EPS - Diluted96.7582.5360.2768.69

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.

06/Balance sheet

Consolidated balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹20,033 Cr
+18.31% YoY
Total liabilities
₹3,272 Cr
Net worth
₹16,761 Cr
Liabilities ÷ assets
16.3%
lower means a lighter balance sheet
Filed order
Total assets20,03316,93215,47014,439
Total liabilities3,2721,9631,8991,672
Net worthderived16,76114,96913,57112,767
Liabilities ÷ assetsderived16.3%11.6%12.3%11.6%
Asset growthderived18.3%9.5%7.1%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets8,9376,8515,7955,127
Current Assets11,09610,0819,6759,312
Total Assets20,03316,93215,47014,439
Current Liabilities2,0431,4521,2781,101
Net Current Asset9,0538,6298,3978,211
Non-Current Liabilities1,229511621571
Equity Capital16,76114,96913,57112,767
Total Equity & Liabilities20,03316,93215,47014,439

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Consolidated cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹2,738 Cr
+65.64% YoY
Investing
-₹2,219 Cr
Financing
-₹804 Cr
Free cash flow
₹519 Cr
operating + investing
Filed order
Operating activities2,7381,6531,2612,460
Operating changereported65.6%31.1%-48.7%—
Investing activities-2,219-804-269-2,708
Investing changereported-176.0%-198.9%90.1%—
Financing activities-804-799-799-797
Financing changereported-0.6%0.0%-0.2%—
Net cash flowderived-28550193-1,045
Free cash flowoperating + investing519849992-248

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax3,3882,9162,1632,369
Income before WC changes3,5013,0312,2442,514
Change in Assets-1,207-699-677506
Change in Liabilities1,30614570-87
Change in WC99-554-607419
Cash flow from Operations2,7381,6531,2612,460
Cash flow from Investing-2,219-804-269-2,708
Cash flow from Financing-804-799-799-797
Total Cash Flow-28550193-1,045
Cash (Start of the year)4133631701,215
Cash (End of the year)128413363170

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
51.88%
0.00 pts QoQ
FII
20.38%
+0.18 pts QoQ
DII (other)
4.50%
-1.01 pts QoQ
Mutual funds
14.66%
+0.79 pts QoQ
Retail & others
8.58%
+0.04 pts QoQ
Filed order
Promoters51.9%51.9%51.9%51.9%
FII20.4%20.2%20.3%20.1%
DII (other)4.5%5.5%5.8%5.5%
Mutual funds14.7%13.9%13.4%13.7%
Retail & others8.6%8.5%8.6%8.8%
Promoters — QoQ changepts, derived0.0%0.0%0.0%—
FII — QoQ changepts, derived0.2%-0.1%0.2%—
DII (other) — QoQ changepts, derived-1.0%-0.3%0.3%—
Mutual funds — QoQ changepts, derived0.8%0.4%-0.3%—
Retail & others — QoQ changepts, derived0.0%-0.1%-0.2%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

DividendFinal₹30.001500.0%24 Jul 202624 Jul 202625 May 2026

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
TORNTPHARMTorrent Pharmaceuticals LPharmaceuticals₹4,689.50+1.70%2.00 L₹1,78,727 Cr$19.86B
LAURUSLABSLaurus Labs LimitedPharmaceuticals₹2,294.60-0.49%8.79 L₹1,24,002 Cr$13.78B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
MANKINDMankind Pharma LimitedPharmaceuticals₹2,665.00+1.37%4.56 L₹1,09,870 Cr$12.21B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
LUPINLupin LimitedPharmaceuticals₹2,014.00+0.76%6.31 L₹91,916 Cr$10.21B
GLENMARKGlenmark PharmaceuticalsPharmaceuticals₹2,648.00+1.51%5.40 L₹74,733 Cr$8.30B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

5102050
  • Thumbnail: Why LIC, Adani Power, NSE, DMart and HAL are not in the NIFTY50 index despite their large market caps
    6h ago21/11/2026, 9:21:48 am
    Why LIC, Adani Power, NSE, DMart and HAL are not in the NIFTY50 index despite their large market caps

    Adani Power, LIC, Divi’s Laboratories, Hindustan Aeronautics, Adani Green Energy and others have high market capitalisation compared to the NIFTY50 bottom five stocks. But despite this, the stock is not part of the NIFTY50 index. Here’s why

Showing 1–1 of 1 article